Atorvia

Atorvia is developing a novel peptide drug to prevent kidney failure during surgery, addressing a significant market with a first-in-class approach. The company is seeking $2M in pre-seed funding to advance its drug towards clinical trials.

By continuing, you agree to share your contact information with Atorvia.